Table 2.

Current Standard of Care.

Drug	Regimen	Median PFS	ORR/CR (%)	Most Common Adverse Effects (%)	Patient Considerations	Evidence
Gemcitabine	1200 mg/m2 on days 1, 8, and 15 of a 28 day cycle for 3–6 cycles	Unknown	50–70/23	Thrombocytopenia (46) Neutropenia (38.5) Transaminitis (36)	None	Zinzani et al. [18]
Romidepsin	14 mg/m2 on days 1, 8, and 15 of 28 day cycles	4 months	25–38/15–18	Nausea (51) Leukopenia (47) Thrombocytopenia (47) Granulocytopenia (45)	Patients with significant cardiac abnormalities were excluded	Piekarz et al. [19] Coiffier et al. [19]
Pralatrexate	30 mg/m2/week for 6 weeks followed by 1 week of rest (7-week cycle). Continued until	3.5 months	29/11	Mucositis (79) Nausea (46) Thrombocytopenia (45) Anemia (38)	Administration of folic acid, B12, and leucovorin needed to prevent AEs	O’Connor et al. [20]
Bendamustine	90–120 mg/m2 D1-2 of 21 day cycles, for up to six cycles,	3.6 months	50/28	Neutropenia (56) * Thrombocytopenia (38) * Infection (20) *	None	Damaj et al. [21]
ICE	Every 15–22 days for 2–3 cycles. Ifosfamide 5 g/m2 on day 2, carboplatin administered on day 2, and dosed to AUC5, and etoposide 100 mg/m2 on days 1 to 3	2 months	20/7	Thrombocytopenia (100) Anemia (100) Leukopenia (100) Nausea (28)	Used for salvage therapy to proceed to HDT/ASCT	Mikesch et al. [22]
Brentuximab Vedotin	120 mg/m2 on days 1 and 2 every 3 weeks for 6 cycles	3.6 months	50/28	Neutropenia (30) * Thrombocytopenia (24) * Infections (20) *		Damaj et al. [21]

*: ≥ Grade 3.